casd1 Antibody

What is CASD1 and why is it important to study?

CASD1 (CAS1 domain containing 1) is a key enzyme responsible for the 9-O-acetylation of sialic acids, which are terminal sugars of glycoproteins and glycolipids. This modification plays crucial roles in development, cellular recognition processes, and host-pathogen interactions. The importance of CASD1 has been definitively established through genetic knockout studies using CRISPR/Cas9 genome editing, which demonstrated that CASD1 deletion completely abolishes the 9-O-acetylation of sialoglycans . The enzyme is particularly significant in ganglioside biology and has been implicated in the survival and drug resistance of acute lymphoblastic leukemia cells, making it a potential therapeutic target .

What applications is the CASD1 antibody validated for?

The CASD1 polyclonal antibody is validated for multiple applications in research settings. According to manufacturer specifications, it is validated for Immunohistochemistry (IHC) at dilutions of 1:200-1:500, Immunocytochemistry/Immunofluorescence (ICC/IF) at 1-4 μg/ml, and Immunohistochemistry-Paraffin (IHC-P) at dilutions of 1:200-1:500 . The antibody specifically detects CASD1 in human samples and can be used to investigate the subcellular localization of CASD1, which research has shown to be predominantly in the Golgi apparatus .

How should CASD1 antibody be stored and handled?

For optimal performance, CASD1 antibody should be stored at 4°C for short-term use. For long-term storage, it is recommended to aliquot the antibody and store at -20°C . This approach minimizes protein degradation by avoiding repeated freeze-thaw cycles, which can compromise antibody integrity and binding efficiency. The antibody is typically supplied in PBS (pH 7.2) with 40% glycerol and 0.02% sodium azide . When handling, researchers should follow standard laboratory safety protocols, particularly due to the presence of sodium azide, which is toxic and can form explosive compounds with metals in plumbing systems.

How can CASD1 antibody be used to study O-acetylation pathways?

CASD1 antibody can be employed in conjunction with virolectin staining to elucidate the sialic acid O-acetylation pathway. Researchers can design experiments comparing CASD1 expression (detected by the antibody) with the presence of 9-O-acetylated sialoglycans (detected by BCoV-HE0-Fc virolectin) . This approach was successfully used to demonstrate that CASD1 expression directly correlates with the presence of 9-O-acetylated sialoglycotopes in the Golgi apparatus. For advanced studies, researchers can combine CASD1 immunostaining with site-directed mutagenesis of key residues (such as S94) to investigate the catalytic mechanism of CASD1 . This methodological approach provides insights into both the localization and functional activity of CASD1 in sialic acid modification pathways.

What experimental designs can validate CASD1 functions using the antibody?

To validate CASD1 functions, researchers can implement a comprehensive experimental design combining genetic manipulation with antibody-based detection:

• Generate CASD1 knockout cells using CRISPR/Cas9 genome editing targeting early exons (as demonstrated with HAP1 and HEK293T cells)

• Perform complementation studies by re-expressing wild-type or mutant CASD1

• Use CASD1 antibody for Western blot and immunofluorescence to confirm knockout and re-expression

• Analyze 9-O-acetylation patterns using specialized lectins (BCoV-HE0-Fc) and monoclonal antibodies against O-acetylated gangliosides (anti-CD60b)

• Perform DMB-HPLC analysis to quantitatively assess changes in Neu5,9Ac2 levels

This experimental framework has successfully demonstrated that CASD1 is essential for 9-O-acetylation of sialic acids and that the S94 residue is critical for its enzymatic function .

How can CASD1 antibody be applied in studies of ganglioside O-acetylation?

For investigating ganglioside O-acetylation, CASD1 antibody can be integrated into a multi-faceted approach:

This approach has been validated in HAP1 cells, where ST8Sia I expression resulted in GD3 (CD60a) formation, but 9-O-acetylated GD3 (CD60b) was only detected in cells with functional CASD1 . By comparing wild-type cells with CASD1 knockout cells, researchers can specifically study the role of CASD1 in the O-acetylation of gangliosides, which has implications for cancer research, particularly in acute lymphoblastic leukemia.

What controls should be included when using CASD1 antibody?

When employing CASD1 antibody in research, the following controls should be implemented:

• Positive control: Cell lines known to express CASD1 (such as CHO cells) should be included

• Negative control:

  • CASD1 knockout cells (HAP1 ΔCASD1 or HEK293T ΔCASD1)

  • Natural CASD1-negative cell lines (such as LM-TK−)

  • Isotype control antibody to assess non-specific binding

• Specificity controls for O-acetylation detection:

  • Alkali treatment to chemically remove O-acetyl groups

  • Treatment with sialate-9-O-acetylesterase to enzymatically remove O-acetyl groups

• Technical controls:

  • Secondary antibody-only control to assess background

  • Blocking peptide competition assay using the immunizing peptide

These controls ensure that any observed staining is specific to CASD1 and provides a framework for interpreting experimental results with confidence.

What are the optimal immunostaining protocols for CASD1 detection?

For optimal CASD1 detection in immunofluorescence studies, the following protocol is recommended:

• Fix cells with 4% paraformaldehyde (10-15 minutes at room temperature)

• Permeabilize with 0.1% Triton X-100 in PBS (5-10 minutes)

• Block with 5% normal serum (from the species of secondary antibody) for 1 hour

• Incubate with CASD1 primary antibody at 1-4 μg/ml in blocking buffer overnight at 4°C

• Wash 3× with PBS

• Incubate with fluorophore-conjugated secondary antibody (1:500-1:1000) for 1 hour at room temperature

• Counterstain nuclei with DAPI

• Mount and image

For paraffin-embedded tissue sections, additional steps include deparaffinization, rehydration, and antigen retrieval (typically using citrate buffer pH 6.0) . The recommended antibody dilution range for IHC-P is 1:200-1:500 . Co-staining with Golgi markers (such as α-Man II) can help confirm the expected subcellular localization of CASD1 .

How can researchers address weak or absent CASD1 immunostaining?

When facing weak or absent CASD1 immunostaining, researchers should systematically troubleshoot using this decision tree:

• Verify antibody functionality:

  • Test antibody on known positive control cells

  • Confirm antibody storage conditions were appropriate

  • Check antibody lot number and validate with manufacturer

• Optimize staining conditions:

  • Increase antibody concentration (up to 2× recommended concentration)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try different antigen retrieval methods for IHC-P

• Check expression levels:

  • Validate CASD1 expression using RT-PCR to detect transcripts

  • Consider that cell lines vary in CASD1 expression; some naturally lack CASD1 (e.g., LM-TK− cells)

• Assess technical factors:

  • Ensure proper cell/tissue fixation and permeabilization

  • Verify secondary antibody compatibility and functionality

  • Minimize background by optimizing blocking conditions

This systematic approach can help identify whether weak staining is due to technical issues or biological variations in CASD1 expression.

How do researchers distinguish between specific and non-specific staining with CASD1 antibody?

Distinguishing specific from non-specific staining requires multiple validation approaches:

• Genetic validation:

  • Compare staining patterns between wild-type and CASD1 knockout cells

  • Perform restoration experiments by re-expressing CASD1 in knockout cells

• Biochemical validation:

  • Preabsorb antibody with the immunizing peptide to block specific binding

  • Use multiple antibodies targeting different CASD1 epitopes

• Pattern recognition:

  • Specific CASD1 staining should localize primarily to the Golgi apparatus

  • Co-localization with Golgi markers supports specificity

  • Diffuse cytoplasmic or nuclear staining may indicate non-specific binding

• Functional correlation:

  • Correlate CASD1 antibody staining with functional readouts like 9-O-acetylated sialic acid detection

  • Loss of both CASD1 staining and 9-O-acetylation in knockout cells strongly supports specificity

These approaches collectively provide strong evidence for staining specificity and help researchers confidently interpret their immunostaining results.

How can CASD1 antibody be used to investigate disease mechanisms?

CASD1 antibody can serve as a valuable tool for investigating disease mechanisms, particularly in cancer research:

• Expression analysis in patient samples:

  • Compare CASD1 expression levels between normal and disease tissues

  • Correlate expression with clinical outcomes and disease progression

• Drug resistance studies:

  • Examine CASD1 expression changes in response to therapy

  • Investigate the relationship between CASD1-mediated 9-O-acetylation and drug resistance in acute lymphoblastic leukemia

• Mechanistic studies:

  • Use CASD1 antibody alongside ganglioside-specific antibodies to analyze changes in 9-O-acetylated gangliosides in disease states

  • Combine with genetic manipulation to establish causative relationships

• Therapeutic target validation:

  • Assess CASD1 as a potential therapeutic target in diseases dependent on 9-O-acetylation

  • Use the antibody to validate target engagement in drug development studies

The Nature Communications article specifically mentions that CASD1 might be a therapeutic target in drug-resistant cancer cells in ALL, whose survival critically depends on 9-O-acetylation .

How might CASD1 antibodies contribute to developing targeted therapeutics?

CASD1 antibodies could significantly advance the development of targeted therapeutics through several research applications:

• Target validation studies:

  • Confirm CASD1 expression in disease tissues using immunohistochemistry

  • Correlate CASD1 levels with disease progression and treatment response

• High-throughput screening:

  • Develop immunoassays using CASD1 antibodies to screen for compounds that modulate CASD1 expression or activity

  • Validate hits by examining effects on 9-O-acetylation patterns

• Mechanism-of-action studies:

  • Use CASD1 antibodies to track protein localization and expression changes in response to experimental therapeutics

  • Investigate whether potential drugs affect CASD1 protein stability, localization, or post-translational modifications

• Companion diagnostics development:

  • Develop CASD1 immunoassays that could identify patients likely to respond to therapies targeting sialic acid O-acetylation pathways

The research indicates that CASD1 could be a particularly promising therapeutic target in acute lymphoblastic leukemia, where 9-O-acetylation appears crucial for cancer cell survival and drug resistance .

What are the emerging techniques for studying CASD1 enzyme kinetics and activity?

Recent advances have enabled more sophisticated analysis of CASD1 enzyme kinetics and activity:

Researchers have successfully used a baculovirus expression system to produce the soluble N-terminal luminal domain of CASD1 (sCASD1) and demonstrated its ability to transfer acetyl groups from acetyl-CoA to CMP-activated sialic acid . These approaches collectively provide a powerful toolkit for detailed characterization of CASD1's catalytic mechanism, potentially informing the design of specific inhibitors.